STOCK TITAN

[SCHEDULE 13D/A] Gryphon Digital Mining, Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

Masimo Corp, identified as a 10% beneficial owner of Neuraxis, Inc. (NRXS), filed a Form 4 disclosing a complete exit from its common-stock position on 1 July 2025.

  • Common-stock sales: 531,548 shares sold at $2.25 per share (Code S); beneficial ownership after this trade: 0 shares.
  • Pre-funded warrant conversion: 289,779 shares acquired via automatic warrant exercise at $0.0001 per share (Code C), immediately followed by the sale of the same 289,779 shares at $2.25 per share (Code S).
  • Derivative position: The pre-funded warrant (exercise price $0.0005) was fully exercised/converted (Code M) and now shows 0 derivative securities outstanding.

Net result: Masimo liquidated a total of 821,327 shares, reducing both its direct and derivative holdings in NRXS to zero. Because Masimo previously qualified as an “insider” under Section 16 (10% owner), the disposal is considered material. The filing does not give reasons for the divestiture nor mention any concurrent corporate events at Neuraxis.

Masimo Corp, identificata come detentrice del 10% delle azioni di Neuraxis, Inc. (NRXS), ha presentato un Modulo 4 comunicando l'uscita completa dalla sua posizione in azioni ordinarie il 1° luglio 2025.

  • Vendite di azioni ordinarie: 531.548 azioni vendute a 2,25 $ per azione (Codice S); proprietà effettiva dopo questa operazione: 0 azioni.
  • Conversione di warrant pre-finanziati: 289.779 azioni acquisite tramite esercizio automatico del warrant a 0,0001 $ per azione (Codice C), seguite immediatamente dalla vendita delle stesse 289.779 azioni a 2,25 $ per azione (Codice S).
  • Posizione derivata: Il warrant pre-finanziato (prezzo di esercizio 0,0005 $) è stato completamente esercitato/convertito (Codice M) e ora non ci sono più titoli derivati in essere.

Risultato netto: Masimo ha liquidato un totale di 821.327 azioni, riducendo sia le sue partecipazioni dirette che quelle derivate in NRXS a zero. Poiché Masimo era precedentemente qualificata come “insider” ai sensi della Sezione 16 (detentore del 10%), la cessione è considerata rilevante. Il modulo non fornisce motivazioni per la dismissione né menziona eventi societari concomitanti in Neuraxis.

Masimo Corp, identificada como propietaria beneficiaria del 10% de Neuraxis, Inc. (NRXS), presentó un Formulario 4 revelando la salida completa de su posición en acciones comunes el 1 de julio de 2025.

  • Ventas de acciones comunes: 531,548 acciones vendidas a $2.25 por acción (Código S); propiedad beneficiaria después de esta operación: 0 acciones.
  • Conversión de warrant prefinanciado: 289,779 acciones adquiridas mediante el ejercicio automático del warrant a $0.0001 por acción (Código C), seguido inmediatamente por la venta de las mismas 289,779 acciones a $2.25 por acción (Código S).
  • Posición derivada: El warrant prefinanciado (precio de ejercicio $0.0005) fue completamente ejercido/convertido (Código M) y ahora no hay valores derivados pendientes.

Resultado neto: Masimo liquidó un total de 821,327 acciones, reduciendo tanto sus tenencias directas como derivadas en NRXS a cero. Debido a que Masimo previamente calificaba como “insider” bajo la Sección 16 (propietario del 10%), la disposición se considera material. La presentación no ofrece razones para la desinversión ni menciona eventos corporativos concurrentes en Neuraxis.

Masimo Corp는 Neuraxis, Inc. (NRXS)의 10% 실소유주로 확인되었으며, 2025년 7월 1일에 보통주 지분 전량을 처분했음을 신고하는 Form 4를 제출했습니다.

  • 보통주 매각: 531,548주를 주당 $2.25에 매도(Code S); 이 거래 후 실소유 지분은 0주입니다.
  • 선납 워런트 전환: 자동 워런트 행사로 주당 $0.0001에 289,779주를 취득(Code C), 즉시 동일 주식 289,779주를 주당 $2.25에 매도(Code S)했습니다.
  • 파생상품 포지션: 선납 워런트(행사가격 $0.0005)가 완전히 행사/전환되어(Code M) 현재 파생증권은 0입니다.

순결과: Masimo는 총 821,327주를 청산하여 NRXS에 대한 직접 및 파생 보유를 모두 0으로 줄였습니다. Masimo는 이전에 섹션 16에 따른 “내부자”(10% 소유자)로 분류되었기에, 이번 처분은 중요한 사항으로 간주됩니다. 제출서에는 처분 사유나 Neuraxis의 동시 기업 이벤트에 대한 언급은 없습니다.

Masimo Corp, identifié comme un détenteur effectif de 10% de Neuraxis, Inc. (NRXS), a déposé un formulaire 4 révélant une sortie complète de sa position en actions ordinaires le 1er juillet 2025.

  • Ventes d’actions ordinaires : 531 548 actions vendues à 2,25 $ par action (Code S) ; propriété effective après cette opération : 0 actions.
  • Conversion de bons de souscription préfinancés : 289 779 actions acquises par exercice automatique du bon à 0,0001 $ par action (Code C), immédiatement suivies par la vente des mêmes 289 779 actions à 2,25 $ par action (Code S).
  • Position dérivée : Le bon de souscription préfinancé (prix d’exercice 0,0005 $) a été entièrement exercé/converti (Code M) et il ne reste désormais aucun titre dérivé en circulation.

Résultat net : Masimo a liquidé un total de 821 327 actions, réduisant ainsi ses participations directes et dérivées dans NRXS à zéro. Étant donné que Masimo était auparavant qualifiée d’« initié » selon la Section 16 (détenteur de 10 %), cette cession est considérée comme significative. Le dépôt ne fournit aucune raison pour cette cession ni ne mentionne d’événements corporatifs concomitants chez Neuraxis.

Masimo Corp, als 10% wirtschaftlicher Eigentümer von Neuraxis, Inc. (NRXS) identifiziert, reichte ein Formular 4 ein, das den vollständigen Ausstieg aus seiner Stammaktienposition am 1. Juli 2025 offenlegt.

  • Verkauf von Stammaktien: 531.548 Aktien zu je 2,25 $ verkauft (Code S); wirtschaftliches Eigentum nach diesem Handel: 0 Aktien.
  • Umwandlung vorfinanzierter Warrants: 289.779 Aktien durch automatische Ausübung des Warrants zu je 0,0001 $ erworben (Code C), unmittelbar gefolgt vom Verkauf derselben 289.779 Aktien zu je 2,25 $ (Code S).
  • Derivative Position: Der vorfinanzierte Warrant (Ausübungspreis 0,0005 $) wurde vollständig ausgeübt/umgewandelt (Code M) und weist nun 0 ausstehende derivative Wertpapiere auf.

Nettoergebnis: Masimo hat insgesamt 821.327 Aktien liquidiert und damit sowohl seine direkten als auch derivativen Bestände an NRXS auf null reduziert. Da Masimo zuvor als „Insider“ gemäß Abschnitt 16 (10% Eigentümer) galt, wird die Veräußerung als wesentlich eingestuft. Die Einreichung gibt keine Gründe für die Veräußerung an und erwähnt keine gleichzeitigen Unternehmensereignisse bei Neuraxis.

Positive
  • None.
Negative
  • Complete divestiture by 10% owner: Masimo sold 821,327 NRXS shares, eliminating its stake and potentially signaling reduced confidence.
  • Loss of strategic alignment: Departure of a major medical-device shareholder may lessen industry support and governance stability.

Insights

TL;DR: 10% owner Masimo sold 100% of its NRXS stake (821k shares) at $2.25, signaling potential insider pessimism.

The Form 4 is impactful because a single holder representing at least 10% ownership has exited completely. Such wholesale sales often raise questions about future prospects or valuation. The $2.25 sale price sets an observable reference point for near-term trading and removes an overhang of warrants and stock. However, the filing contains no performance metrics or corporate context, so investors should avoid over-extrapolating motives. Taken at face value, insider supply pressure is gone, but the loss of a strategic shareholder like Masimo may reduce perceived sponsorship.

TL;DR: Strategic shareholder exit alters governance dynamics; watch ownership concentration and voting control.

Masimo’s departure eliminates a large, potentially stabilizing block holder. This shifts NRXS’s ownership landscape, possibly increasing influence of remaining insiders or public float volatility. The warrant exercise and immediate sale clarify capital-structure cleanup—no residual cheap securities remain. Nevertheless, sudden disengagement by an aligned medical-technology peer could be viewed negatively by governance-focused investors who value long-term strategic backing.

Masimo Corp, identificata come detentrice del 10% delle azioni di Neuraxis, Inc. (NRXS), ha presentato un Modulo 4 comunicando l'uscita completa dalla sua posizione in azioni ordinarie il 1° luglio 2025.

  • Vendite di azioni ordinarie: 531.548 azioni vendute a 2,25 $ per azione (Codice S); proprietà effettiva dopo questa operazione: 0 azioni.
  • Conversione di warrant pre-finanziati: 289.779 azioni acquisite tramite esercizio automatico del warrant a 0,0001 $ per azione (Codice C), seguite immediatamente dalla vendita delle stesse 289.779 azioni a 2,25 $ per azione (Codice S).
  • Posizione derivata: Il warrant pre-finanziato (prezzo di esercizio 0,0005 $) è stato completamente esercitato/convertito (Codice M) e ora non ci sono più titoli derivati in essere.

Risultato netto: Masimo ha liquidato un totale di 821.327 azioni, riducendo sia le sue partecipazioni dirette che quelle derivate in NRXS a zero. Poiché Masimo era precedentemente qualificata come “insider” ai sensi della Sezione 16 (detentore del 10%), la cessione è considerata rilevante. Il modulo non fornisce motivazioni per la dismissione né menziona eventi societari concomitanti in Neuraxis.

Masimo Corp, identificada como propietaria beneficiaria del 10% de Neuraxis, Inc. (NRXS), presentó un Formulario 4 revelando la salida completa de su posición en acciones comunes el 1 de julio de 2025.

  • Ventas de acciones comunes: 531,548 acciones vendidas a $2.25 por acción (Código S); propiedad beneficiaria después de esta operación: 0 acciones.
  • Conversión de warrant prefinanciado: 289,779 acciones adquiridas mediante el ejercicio automático del warrant a $0.0001 por acción (Código C), seguido inmediatamente por la venta de las mismas 289,779 acciones a $2.25 por acción (Código S).
  • Posición derivada: El warrant prefinanciado (precio de ejercicio $0.0005) fue completamente ejercido/convertido (Código M) y ahora no hay valores derivados pendientes.

Resultado neto: Masimo liquidó un total de 821,327 acciones, reduciendo tanto sus tenencias directas como derivadas en NRXS a cero. Debido a que Masimo previamente calificaba como “insider” bajo la Sección 16 (propietario del 10%), la disposición se considera material. La presentación no ofrece razones para la desinversión ni menciona eventos corporativos concurrentes en Neuraxis.

Masimo Corp는 Neuraxis, Inc. (NRXS)의 10% 실소유주로 확인되었으며, 2025년 7월 1일에 보통주 지분 전량을 처분했음을 신고하는 Form 4를 제출했습니다.

  • 보통주 매각: 531,548주를 주당 $2.25에 매도(Code S); 이 거래 후 실소유 지분은 0주입니다.
  • 선납 워런트 전환: 자동 워런트 행사로 주당 $0.0001에 289,779주를 취득(Code C), 즉시 동일 주식 289,779주를 주당 $2.25에 매도(Code S)했습니다.
  • 파생상품 포지션: 선납 워런트(행사가격 $0.0005)가 완전히 행사/전환되어(Code M) 현재 파생증권은 0입니다.

순결과: Masimo는 총 821,327주를 청산하여 NRXS에 대한 직접 및 파생 보유를 모두 0으로 줄였습니다. Masimo는 이전에 섹션 16에 따른 “내부자”(10% 소유자)로 분류되었기에, 이번 처분은 중요한 사항으로 간주됩니다. 제출서에는 처분 사유나 Neuraxis의 동시 기업 이벤트에 대한 언급은 없습니다.

Masimo Corp, identifié comme un détenteur effectif de 10% de Neuraxis, Inc. (NRXS), a déposé un formulaire 4 révélant une sortie complète de sa position en actions ordinaires le 1er juillet 2025.

  • Ventes d’actions ordinaires : 531 548 actions vendues à 2,25 $ par action (Code S) ; propriété effective après cette opération : 0 actions.
  • Conversion de bons de souscription préfinancés : 289 779 actions acquises par exercice automatique du bon à 0,0001 $ par action (Code C), immédiatement suivies par la vente des mêmes 289 779 actions à 2,25 $ par action (Code S).
  • Position dérivée : Le bon de souscription préfinancé (prix d’exercice 0,0005 $) a été entièrement exercé/converti (Code M) et il ne reste désormais aucun titre dérivé en circulation.

Résultat net : Masimo a liquidé un total de 821 327 actions, réduisant ainsi ses participations directes et dérivées dans NRXS à zéro. Étant donné que Masimo était auparavant qualifiée d’« initié » selon la Section 16 (détenteur de 10 %), cette cession est considérée comme significative. Le dépôt ne fournit aucune raison pour cette cession ni ne mentionne d’événements corporatifs concomitants chez Neuraxis.

Masimo Corp, als 10% wirtschaftlicher Eigentümer von Neuraxis, Inc. (NRXS) identifiziert, reichte ein Formular 4 ein, das den vollständigen Ausstieg aus seiner Stammaktienposition am 1. Juli 2025 offenlegt.

  • Verkauf von Stammaktien: 531.548 Aktien zu je 2,25 $ verkauft (Code S); wirtschaftliches Eigentum nach diesem Handel: 0 Aktien.
  • Umwandlung vorfinanzierter Warrants: 289.779 Aktien durch automatische Ausübung des Warrants zu je 0,0001 $ erworben (Code C), unmittelbar gefolgt vom Verkauf derselben 289.779 Aktien zu je 2,25 $ (Code S).
  • Derivative Position: Der vorfinanzierte Warrant (Ausübungspreis 0,0005 $) wurde vollständig ausgeübt/umgewandelt (Code M) und weist nun 0 ausstehende derivative Wertpapiere auf.

Nettoergebnis: Masimo hat insgesamt 821.327 Aktien liquidiert und damit sowohl seine direkten als auch derivativen Bestände an NRXS auf null reduziert. Da Masimo zuvor als „Insider“ gemäß Abschnitt 16 (10% Eigentümer) galt, wird die Veräußerung als wesentlich eingestuft. Die Einreichung gibt keine Gründe für die Veräußerung an und erwähnt keine gleichzeitigen Unternehmensereignisse bei Neuraxis.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Anchorage Lending CA, LLC
Signature:/s/ Margaret Vaden
Name/Title:Margaret Vaden / General Counsel
Date:07/03/2025
Anchor Labs, Inc.
Signature:/s/ Margaret Vaden
Name/Title:Margaret Vaden / General Counsel
Date:07/03/2025

FAQ

How many NRXS shares did Masimo sell on 1 July 2025?

Masimo disposed of 531,548 existing shares and 289,779 newly issued shares, totaling 821,327 shares.

Did Masimo exercise any warrants in this filing?

Yes. A pre-funded warrant for 289,779 shares was exercised at $0.0005 per share and immediately sold.

What is Masimo’s remaining ownership in Neuraxis (NRXS)?

Post-transaction, Masimo reports zero common shares and zero derivative securities owned.

At what price were the NRXS shares sold?

All common-stock sales were executed at $2.25 per share.

Why is a Form 4 filing by a 10% owner significant?

Section 16 insiders’ trades can indicate sentiment and materially affect float and governance, making them closely watched by investors.
Gryphon Digital

NASDAQ:GRYP

GRYP Rankings

GRYP Latest News

GRYP Latest SEC Filings

GRYP Stock Data

61.16M
53.83M
39.1%
3.36%
1.64%
Capital Markets
Finance Services
Link
United States
LAS VEGAS